https://www.selleckchem.com/
12, 95% CI (0.08, 0.21), I 2 = 0%, p less then 0.00001] but lesser than that of propofol [OR = 12.22, 95% CI (1.58, 94.47), I 2 = 0%, p = 0.02]. Regarding the adverse events, remimazolam is associated with a lower incidence of hypotension than placebo and midazolam. Similarly, remimazolam was associated with a lower incidence of hypotension and hypoxemia than propofol. Conclusions Remimazolam is a safe and effective sedative for patients undergoing endoscopic procedures. The sedative efficiency of remimazolam was significantly higher than that of midazolam
Like
Comment
Share
